More light for Clinuvel
Tuesday, 23 September, 2008
Clinuvel Pharmaceuticals (ASX: CUV) has begun phase II trials of its photoprotective drug afamelanotide (CUV1657) in patients undergoing photodynamic therapy (PDT).
The trial is being conducted in a Parisian hospital and will extend to multiple health-care centres in France.
The first four of an anticipated 30 patients have been dosed, and results are expected within 12 months.
PDT is used to eradicate pre-malignant lesions of the oesophagus and as a palliative therapy in bile duct cancer. It involves administration of porfimer sodium, a photosensitiser, and a targeted light source.
One side effect is phototoxicity, with patients unable to tolerate UV light. Clinuvel anticipates that afamelanotide may offer a photoprotective effect.
Clinuvel is currently in Phase III trials of CUV1657 in erythropoietic protoporphyria (EPP), or abnormal sun sensitivity.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
